Compositions and methods for binding sphingosine-1-phosphate

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S387300, C530S388100, C424S130100, C424S133100, C424S134100

Reexamination Certificate

active

07829674

ABSTRACT:
The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.

REFERENCES:
patent: 4150949 (1979-04-01), Smith
patent: 4816450 (1989-03-01), Bell et al.
patent: 4937232 (1990-06-01), Bell et al.
patent: 5079263 (1992-01-01), Zeeck et al.
patent: 5137919 (1992-08-01), Igarashi et al.
patent: 5151360 (1992-09-01), Handa et al.
patent: 5248824 (1993-09-01), Igrashi et al.
patent: 5260288 (1993-11-01), Igarashi et al.
patent: 5331014 (1994-07-01), Kimura et al.
patent: 5369030 (1994-11-01), Hannun et al.
patent: 5391800 (1995-02-01), Igrashi et al.
patent: 5430160 (1995-07-01), Holton
patent: 5444087 (1995-08-01), Patel et al.
patent: 5585476 (1996-12-01), MacLennan et al.
patent: 5627171 (1997-05-01), Park et al.
patent: 5663404 (1997-09-01), Igarashi et al.
patent: 5677288 (1997-10-01), Marangos
patent: 5677337 (1997-10-01), Wei et al.
patent: 5851782 (1998-12-01), Hannun et al.
patent: 5877167 (1999-03-01), Igarashi et al.
patent: 5919687 (1999-07-01), Chatterjee
patent: 5929039 (1999-07-01), Woodcock et al.
patent: 5989803 (1999-11-01), Tabas et al.
patent: 6051598 (2000-04-01), Shayman et al.
patent: 6057126 (2000-05-01), Munroe et al.
patent: 6130067 (2000-10-01), Tsui
patent: 6140060 (2000-10-01), Chun et al.
patent: 6187562 (2001-02-01), Duckworth et al.
patent: 6210976 (2001-04-01), Sabbadini
patent: 6284798 (2001-09-01), Amtmann et al.
patent: 6306911 (2001-10-01), Wachter et al.
patent: 6323201 (2001-11-01), Carson et al.
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 6352844 (2002-03-01), Maurer et al.
patent: 6423527 (2002-07-01), Saba et al.
patent: 6534322 (2003-03-01), Sabbadini
patent: 6534323 (2003-03-01), Sabbadini
patent: 6610835 (2003-08-01), Liotta et al.
patent: 6613322 (2003-09-01), Tabas et al.
patent: 6649362 (2003-11-01), Gamble et al.
patent: 6858383 (2005-02-01), Sabbadini
patent: 6881546 (2005-04-01), Sabbadini
patent: 7169390 (2007-01-01), Sabbadini
patent: 2001/0041688 (2001-11-01), Waeber et al.
patent: 2002/0150582 (2002-10-01), Friedrichs et al.
patent: 2003/0125533 (2003-07-01), Kossida et al.
patent: 2003/0219782 (2003-11-01), Saba et al.
patent: 2007/0148168 (2007-06-01), Sabbadini et al.
patent: 0173648 (1986-03-01), None
patent: 0173663 (1986-03-01), None
patent: 09-110722 (1987-04-01), None
patent: 2000-293181 (2000-10-01), None
patent: WO 97/44019 (1997-11-01), None
patent: WO 98/03529 (1998-01-01), None
patent: WO 98/28445 (1998-07-01), None
patent: WO 98/40349 (1998-09-01), None
patent: WO 98/57179 (1998-12-01), None
patent: WO 99/07855 (1999-02-01), None
patent: WO 99/12890 (1999-03-01), None
patent: WO 99/16888 (1999-04-01), None
patent: WO 99/33972 (1999-07-01), None
patent: WO 99/38983 (1999-08-01), None
patent: WO 99/41265 (1999-08-01), None
patent: WO 99/41266 (1999-08-01), None
patent: WO 99/46277 (1999-09-01), None
patent: WO 99/61581 (1999-12-01), None
patent: WO 00/00593 (2000-01-01), None
patent: WO 00/21919 (2000-04-01), None
patent: WO 00/40262 (2000-07-01), None
patent: WO 00/52173 (2000-09-01), None
patent: WO 00/56135 (2000-09-01), None
patent: WO 00/58448 (2000-10-01), None
patent: WO 00/58491 (2000-10-01), None
patent: WO 00/59517 (2000-10-01), None
patent: WO 00/70028 (2000-11-01), None
patent: WO 00/72833 (2000-12-01), None
patent: WO 01/04108 (2001-01-01), None
patent: WO 01/04139 (2001-01-01), None
patent: WO 01/07418 (2001-02-01), None
patent: WO 01/31029 (2001-05-01), None
patent: WO 01/38295 (2001-05-01), None
patent: WO 01/55410 (2001-08-01), None
patent: WO 01/57057 (2001-08-01), None
patent: WO 01/60990 (2001-08-01), None
patent: WO 01/71045 (2001-09-01), None
patent: WO 01/72701 (2001-10-01), None
patent: WO 01/80903 (2001-11-01), None
patent: WO 01/85953 (2001-11-01), None
Skolnick and Fetrow. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology, 2000. vol. 18, pp. 34-39.
Burgess, Shaheen, Ravera, Jaye, Donohue, and Winkles. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor 1 from its receptor binding activities by site-directed mutagenesis of a single lysine residue. Journal of Cell Biology, 1990. vol. 111, pp. 2129-2138.
Lazar, Watanabe, Dalton, and Sporn. Transforming growth factor a: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology, 1988. vol. 8, pp. 1247-1252.
Holm, Jafari, and Sundstrom. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Molecular Immunology, 2007. vol. 44, pp. 1075-1084.
Chen, Weismann, Fuh, Li, Christinger, Mc Kay, De Vos, and Lowman. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. Journal of Molecular Biology, 1999. vol. 293, pp. 865-881.
Rudikoff, Giusti, Cook, and Scharff. Single amino acid substitution altering antigen binding specificity. Proceedings of the National Academy of Sciences, 1982. vol. 79, pp. 1979-1983.
Mac Callum, Martin, and Thornton. Antibody-antigen interactions: contact analysis and binding site topography. Journal of Molecular Biology, 1996. vol. 262, pp. 732-745.
De Pascalis, Iwahashi, Tamura, Padlan, Gonzales, Santos, Giuliano, Schuck, Schlom, and Kashmiri. Grafting of “abbreviated” complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. Journal of Immunology, 2002. vol. 169, pp. 3076-3084.
Casset, Roux, Mouchet, Bes, Chardes, Granier, Mani, Pugniere, Laune, Pau, Kaczorek, Lahana, and Rees. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 2003. vol. 307, pp. 198-205.
Vajdos, Adams, Breece, Presta, De Vos, and Sidhu. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. Journal of Molecular Biology, 2002. vol. 320, pp. 415-428.
Wu, Nie, Huse, and Watkins. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. Journal of Molecular Biology, 1999. vol. 294, pp. 151-162.
Abe et al., “Structural and stereochemical studies of potent inhibitors and glucosylceramide synthase and tumor cell growth,”J. Lipid Res.36(3):611-621 (1995).
Abe et al., “Glycosphingolipid depletion in Fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase,”Kidney Int.57(2):446-454 (2000).
Abe et al., “Use of Sulfobutyl Ether-Cyclodextrin as a Vehicle for D-threo-1-Phenyl-2-decanoylamino-3-morpholinopropanol-Related Glucosylceramide Synthase Inhibitors,”Anal. Biochem.287(2):344-347 (2000).
Ambati, “Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies,”Surv. Ophthalmol.48(3):257-293 (2003) (Abstract Only).
An et al., “Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids,”FEBS Letts.417(3):279-282 (1997).
An et al., “Characterization of a Novel Subtype of Human G Protein-coupled Receptor for Lysophosphotatidic Acid,”J. Biol. Chem.273(14):7906-7910 (1998).
An et al., “Sphingosine 1-phosphate-induced cell proliferation, survival, and related signaling events mediated by G protein-coupled receptors Edg3 and Edg5,”J. Biol. Chem.275(1):288-296 (2000).
Ancellin et al., “Extracelluar export of sphingosine kinase-1 enzyme: Sphingosine 1 phosphate generation and the induction of angiogenic vascular maturation,”J. Biol. Chem.277(8):6667-6675 (2001).
Andrieu-Abadie et al., “L-camitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation,”FASEB J.13(12):1501-1510 (1999).
Arenz et al., “Synthese des ersten selektiven irreverilben I

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Compositions and methods for binding sphingosine-1-phosphate does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for binding sphingosine-1-phosphate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for binding sphingosine-1-phosphate will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4190846

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.